OBJECTIVE: To examine the long-term effects of individual antiretroviral drugs on body composition among 416 persons initiating antiretroviral therapy (ART). METHODS: In a substudy of a clinical trial of persons initiating ART, changes in body composition attributable to individual ART were examined. ARTs assessed were as follows: indinavir, ritonavir, nelfinavir, efavirenz, nevirapine, stavudine (d4T), zidovudine (ZDV), lamivudine (3TC), didanosine, and abacavir. Skinfolds and circumferences were measured at baseline and every 4 months. Mid arm, mid thigh, and waist subcutaneous tissue areas and nonsubcutaneous tissue areas were calculated. Rates of change per year of exposure to each individual ART drug were determined using multivariate longitudinal regression. RESULTS: d4T and ZDV use was associated with losses in subcutaneous tissue area and skinfold thickness. 3TC use was associated with gains in all subcutaneous tissue areas and skinfold thickness, whereas abacavir use was associated with an increase in waist subcutaneous tissue area. Indinavir was associated with gains in waist subcutaneous tissue area, whereas indinavir, efavirenz, and nevirapine were associated with increases in upper back skinfolds. d4T use was also associated with increases in all nonsubcutaneous tissue areas; 3TC use was associated with the greatest increase in waist nonsubcutaneous tissue area. CONCLUSION: In this prospective nonrandomized evaluation, the nucleoside reverse transcriptase inhibitors d4T and ZDV were associated with decreases in subcutaneous tissue areas, whereas 3TC use was associated with increased subcutaneous tissue areas and waist nonsubcutaneous tissue area.
RCT Entities:
OBJECTIVE: To examine the long-term effects of individual antiretroviral drugs on body composition among 416 persons initiating antiretroviral therapy (ART). METHODS: In a substudy of a clinical trial of persons initiating ART, changes in body composition attributable to individual ART were examined. ARTs assessed were as follows: indinavir, ritonavir, nelfinavir, efavirenz, nevirapine, stavudine (d4T), zidovudine (ZDV), lamivudine (3TC), didanosine, and abacavir. Skinfolds and circumferences were measured at baseline and every 4 months. Mid arm, mid thigh, and waist subcutaneous tissue areas and nonsubcutaneous tissue areas were calculated. Rates of change per year of exposure to each individual ART drug were determined using multivariate longitudinal regression. RESULTS:d4T and ZDV use was associated with losses in subcutaneous tissue area and skinfold thickness. 3TC use was associated with gains in all subcutaneous tissue areas and skinfold thickness, whereas abacavir use was associated with an increase in waist subcutaneous tissue area. Indinavir was associated with gains in waist subcutaneous tissue area, whereas indinavir, efavirenz, and nevirapine were associated with increases in upper back skinfolds. d4T use was also associated with increases in all nonsubcutaneous tissue areas; 3TC use was associated with the greatest increase in waist nonsubcutaneous tissue area. CONCLUSION: In this prospective nonrandomized evaluation, the nucleoside reverse transcriptase inhibitors d4T and ZDV were associated with decreases in subcutaneous tissue areas, whereas 3TC use was associated with increased subcutaneous tissue areas and waist nonsubcutaneous tissue area.
Authors: R D MacArthur; L Chen; D L Mayers; C L Besch; R Novak; M van den Berg-Wolf; T Yurik; G Peng; B Schmetter; B Brizz; D Abrams Journal: Control Clin Trials Date: 2001-04
Authors: J R Bogner; V Vielhauer; R A Beckmann; G Michl; L Wille; B Salzberger; F D Goebel Journal: J Acquir Immune Defic Syndr Date: 2001-07-01 Impact factor: 3.731
Authors: K A Lichtenstein; D J Ward; A C Moorman; K M Delaney; B Young; F J Palella; P H Rhodes; K C Wood; S D Holmberg Journal: AIDS Date: 2001-07-27 Impact factor: 4.177
Authors: Andrew Carr; Cassy Workman; Don E Smith; Jennifer Hoy; Jeff Hudson; Nicholas Doong; Allison Martin; Janaki Amin; Judith Freund; Matthew Law; David A Cooper Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Rebecca Scherzer; Wei Shen; Peter Bacchetti; Donald Kotler; Cora E Lewis; Michael G Shlipak; Steven B Heymsfield; Carl Grunfeld Journal: Am J Clin Nutr Date: 2008-06 Impact factor: 7.045
Authors: Kristine M Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Pablo Tebas; Kathleen Melbourne; Belinda Ha; Nasreen C Jahed; Grace A McComsey Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski Journal: World J Virol Date: 2015-05-12